Neurogene (NGNE) Current Assets (2013 - 2026)
Neurogene's (NGNE) quarterly Current Assets came in at $246.7 million in Q1 2026, down 16.75% YoY from $296.4 million in Q1 2025, and down 9.21% on a QoQ basis from $271.8 million in Q4 2025.
Neurogene (NGNE) Current Assets (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Current Assets data on file, last reported at $246.7 million in Q1 2026.
- Quarterly Current Assets fell 16.75% year-over-year to $246.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $246.7 million (down 16.75% YoY) and the FY2025 annual result came in at $271.8 million, down 13.98% from the prior year.
- Current Assets declined to $246.7 million in Q1 2026, from $271.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $315.9 million in Q4 2024 to a low of $79.9 million in Q3 2023.
- A 5-year average of $179.4 million and a median of $159.1 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets sank 41.16% — and 2023, when it jumped 136.49%.
- Tracing NGNE's Current Assets over 5 years: stood at $84.7 million in 2022, then jumped by 136.49% to $200.3 million in 2023, then soared by 57.69% to $315.9 million in 2024, then fell by 13.98% to $271.8 million in 2025, then dropped by 9.21% to $246.7 million in 2026.
- The last three Current Assets figures came in at $246.7 million (Q1 2026), $271.8 million (Q4 2025), and $270.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 228.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228.91 Mn |
| Mar 31, 2026 | 246.75 Mn |
| Dec 31, 2025 | 271.77 Mn |
| Sep 30, 2025 | 270.52 Mn |
| Jun 30, 2025 | 278.99 Mn |
| Mar 31, 2025 | 296.40 Mn |
| Dec 31, 2024 | 315.92 Mn |
| Sep 30, 2024 | 143.65 Mn |
| Jun 30, 2024 | 159.15 Mn |
| Mar 31, 2024 | 174.14 Mn |
| Dec 31, 2023 | 200.35 Mn |
| Sep 30, 2023 | 79.89 Mn |
| Jun 30, 2023 | 83.78 Mn |
| Mar 31, 2023 | 85.64 Mn |
| Dec 31, 2022 | 84.72 Mn |
| Sep 30, 2022 | 108.86 Mn |
| Jun 30, 2022 | 118.49 Mn |
| Mar 31, 2022 | 130.37 Mn |
| Dec 31, 2021 | 143.99 Mn |
| Sep 30, 2021 | 156.50 Mn |